ReviewLife (Basel, Switzerland)2024
Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators.
Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Eosinophil Extracellular Traps in Health and Disease: From Host Defense to Chronic Inflammation.Biomedicines · 2026Review
- In Vivo Confocal Microscopy Revealed Alteration of Limbal Stem Cells and Sub-Basal Nerve Plexus in Allergic and Dry Eye-Related Ocular Surface Diseases.Translational vision science & technology · 2026Article
- Inflammatory Mediators Involved in Conjunctival and Corneal Remodeling of Vernal Keratoconjunctivitis.Life (Basel, Switzerland) · 2026Review
- Reduced Levels of Resolvin D1 and Thrombospondin-1 in Vernal Keratoconjunctivitis.Journal of clinical practice and research · 2026Article
- Ocular Allergy Within the Framework of the EAACI Nomenclature of Allergic Diseases and Hypersensitivity Reactions.Allergy, asthma & immunology research · 2026Review
- The Effects of Eye Rubbing on Corneal Topography and Biomechanics in Children With Allergic Conjunctivitis.Translational vision science & technology · 2025Observational
- Article
- Ocular Manifestations in Children with Vernal Keratoconjunctivitis.Children (Basel, Switzerland) · 2025Review
- The evolving role of ciclosporin in the management of vernal keratoconjunctivitis.Frontiers in ophthalmology · 2025Review
- A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis.Diagnostics (Basel, Switzerland) · 2024Article
- Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends.Life (Basel, Switzerland) · 2024Review
- Topical tacrolimus versus dexamethasone in managing shield ulcer of vernal keratoconjunctivitis.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vernal keratoconjunctivitis (VKC) is a complex and multifactorial disease process that employs Th2 cell-mediated immunologic processes, which involves the overexpression of interleukin 4 (IL-4), IL-5, IL-9, IL-13, and IL-31, and the activation of mast cells that release IL-5 and CCL-11, recruiting eosinophils to the site of inflammation. The disease primarily affects young males and is more common in regions with warm climates. VKC is characterized by persistent and recurrent conjunctival inflammation that can adversely affect the patient's quality of life, and, when inadequately treated, may lead to a host of ocular complications, such as corneal shield ulcers and scarring. The major distinct forms of VKC include limbal or palpebral, which may occur in combination. The clinicopathological features of VKC include the presence of pseudogerontoxon, limbal gelatinous hyperplasia, and perilimbal hyperpigmentation. Topical immunomodulators are effective anti-steroidal options for controlling severe and chronic cases of VKC. This review will provide a brief overview of topical immunomodulators, including cyclosporin and tacrolimus, and will highlight the clinical manifestations, pathological mechanisms, and fibroproliferative changes in the conjunctiva that can result from recurrent disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.